Related Experiment Videos
Sodium thiophene carboxylate does not facilitate expectoration
1Dept of Internal Medicine, University Hospital, Zurich, Switzerland.
The European Respiratory Journal
|June 1, 1991
Summary
Sodium thiophene carboxylate, studied for chronic bronchitis, showed no significant clinical benefit over placebo. This expectorant and mucoregulatory drug lacks proven effectiveness in treating stable chronic bronchitis patients.
Area of Science:
- Respiratory Medicine
- Clinical Pharmacology
Background:
- Stable chronic bronchitis presents ongoing respiratory challenges.
- Effective mucoregulatory and expectorant therapies are crucial for symptom management.
Purpose of the Study:
- To evaluate the clinical effectiveness of sodium thiophene carboxylate compared to placebo.
- To assess its impact on subjective symptoms, pulmonary function, and sputum characteristics in chronic bronchitis.
Main Methods:
- A randomized, double-blind, crossover study design was employed.
- 33 patients with stable chronic bronchitis participated over a seven-week trial.
- Data collection included subjective symptom reporting, pulmonary function tests, and sputum analysis.
Main Results:
- No statistically significant advantage of sodium thiophene carboxylate over placebo was observed.
- Subjective assessments of overall clinical efficacy did not differ between the treatment groups.
- Pulmonary function tests and sputum characteristics showed no significant improvement with sodium thiophene carboxylate.
Conclusions:
- Sodium thiophene carboxylate, while potentially acting as an expectorant, demonstrated no clinical effectiveness in this study.
- Current evidence does not support its use for treating stable chronic bronchitis.